8-K: Sanuwave Settles Debt, Shifts Exchange Listing, and Extends Merger Deadline

Sanuwave Health has settled a significant debt, changed its exchange listing application from Nasdaq to Cboe BZX, and extended its merger deadline with SEPA.

Summary

• Sanuwave Health has paid $2.075 million to settle a $6.3 million debt and interest owed to Celularity, stemming from the 2020 UltraMist acquisition.
• The payment was funded through a capital raise involving many of the company's long-term shareholders.
• The company has withdrawn its Nasdaq listing application due to an interpretation of the exchange rules requiring a $4 minimum bid for 90 trading days prior to listing.
• Sanuwave has submitted a new listing application to the Cboe BZX Exchange, which is currently under review.
• The merger outside date with SEPA has been extended to June 30, 2024.
• Sanuwave has been granted a unilateral right to terminate the merger agreement with SEPA at any time.
• The company reaffirms its financial guidance for Q2 2024, projecting a 45-55% revenue increase compared to Q2 2023 and gross margins in the mid-70s.
• Full-year 2024 revenue is projected to exceed $30 million, representing a 50% growth compared to FY 2023.
• Sanuwave believes it is sufficiently funded for the remainder of 2024 and that its operations can be self-funding.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the debt settlement and strong revenue projections are positive, the delay in the merger and exchange listing is a setback. The company's ability to self-fund operations is a positive sign, but the risks associated with the merger and listing process temper the overall sentiment.

Positives

• The settlement of the $6.3 million debt for $2.075 million significantly improves the company's financial position.
• The company is projecting strong revenue growth for both Q2 and the full year 2024.
• Sanuwave believes it is currently sufficiently funded for the remainder of 2024 and that its operations can be self-funding.
• The company has secured the right to unilaterally terminate the merger agreement with SEPA, providing flexibility.

Negatives

• The withdrawal of the Nasdaq listing application and the need to apply to the Cboe BZX Exchange indicates a setback in the company's uplisting plans.
• The merger with SEPA has been delayed, with the outside date extended to June 30, 2024.
• The company expected to secure Cboe listing, close the transaction, and commence trading in May, but the application process has taken longer than anticipated.

Risks

• The merger with SEPA may not be completed if the Cboe BZX listing is not secured or if other closing conditions are not met.
• The company's actual financial results may differ from its projections.
• There are risks associated with the company's ability to maintain its listing on a national securities exchange.
• The company is subject to various economic, business, and competitive factors that could adversely affect its performance.

Future Outlook

Sanuwave expects to secure a listing on the Cboe BZX Exchange and close the merger with SEPA by June 30, 2024. The company also plans to proceed with activities that were part of the SEPA transaction, such as a note and warrant exchange, a reverse stock split, and other corporate financing activities.

Management Comments

• Morgan Frank, CEO, stated that the purpose of the merger with SEPA was to simplify and strengthen Sanuwave's financial position and structure to allow the Company to be valued for its business as opposed to its capital structure.

Industry Context

The announcement reflects the challenges faced by companies seeking to uplist to national exchanges and the importance of maintaining financial stability. The shift to the Cboe BZX Exchange is a strategic move to overcome Nasdaq listing requirements. The company's focus on wound care products aligns with the growing demand for regenerative medicine solutions.

Comparison to Industry Standards

• While specific competitor data is not provided, the projected 50% revenue growth for FY 2024 is significant and suggests strong market traction for Sanuwave's products.
• The debt settlement is a positive step, as many small cap companies struggle with legacy debt.
• The move to the Cboe BZX Exchange is not uncommon for companies that do not meet the stringent requirements of the Nasdaq, and is a common strategy for companies seeking to uplist.
• The company's focus on regenerative medicine aligns with a growing trend in the healthcare industry, with companies like Organogenesis and Integra LifeSciences also operating in this space.

Stakeholder Impact

• Shareholders will be impacted by the potential merger and listing on a new exchange.
• Employees may be affected by the changes in the company's structure and operations.
• Customers may benefit from the company's continued growth and development of wound care products.
• Creditors have seen a significant debt settlement, improving the company's financial health.

Next Steps

• Sanuwave will continue the application process for listing on the Cboe BZX Exchange.
• The company will seek to close the merger with SEPA by June 30, 2024.
• Sanuwave will begin work on activities that were part of the SEPA transaction, such as the note and warrant exchange, a reverse stock split, and other corporate financing activities.

Key Dates

Keywords

merger, SEPA, listing, Cboe BZX Exchange, Nasdaq, debt settlement, capital raise, revenue growth, financial guidance, wound care